このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Vita Life Sciences 過去の業績

過去基準チェック /46

Vita Life Sciencesは、平均年間23.9%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間35.6% 13.6%収益成長率で成長しています。 Vita Life Sciencesの自己資本利益率は21%であり、純利益率は12.2%です。

主要情報

19.8%

収益成長率

19.7%

EPS成長率

Pharmaceuticals 業界の成長	31.2%
収益成長率	14.1%
株主資本利益率	19.3%
ネット・マージン	11.9%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

Vita Life Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

CHIA:VLS 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費
30 Jun 24	79	9	34
31 Mar 24	77	9	32
31 Dec 23	74	9	31
30 Sep 23	71	8	30
30 Jun 23	69	7	29
31 Mar 23	68	7	29
31 Dec 22	67	7	29
30 Sep 22	65	8	27
30 Jun 22	64	8	26
31 Mar 22	61	8	25
31 Dec 21	57	8	24
30 Sep 21	54	8	23
30 Jun 21	50	7	22
31 Mar 21	48	6	22
31 Dec 20	46	6	21
30 Sep 20	46	6	22
30 Jun 20	45	5	22
31 Mar 20	44	4	23
31 Dec 19	42	3	23
30 Sep 19	42	2	23
30 Jun 19	41	2	23
31 Mar 19	41	2	22
31 Dec 18	41	2	21
30 Sep 18	40	3	21
30 Jun 18	40	4	21
31 Mar 18	38	3	20
31 Dec 17	37	3	20
30 Sep 17	37	3	20
30 Jun 17	37	3	20
31 Mar 17	38	3	20
31 Dec 16	38	3	20
30 Sep 16	38	4	20
30 Jun 16	38	5	20
31 Mar 16	39	5	21
31 Dec 15	39	4	21
30 Sep 15	38	4	20
30 Jun 15	37	4	20
31 Mar 15	37	6	20
31 Dec 14	37	7	19
30 Sep 14	36	7	19
30 Jun 14	36	7	19
31 Mar 14	36	6	19
31 Dec 13	35	5	18

質の高い収益: VLSは高品質の収益を持っています。

利益率の向上: VLSの現在の純利益率 (12.2%)は、昨年(10.6%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: VLSの収益は過去 5 年間で年間19.8%増加しました。

成長の加速: VLSの過去 1 年間の収益成長率 ( 28.2% ) は、5 年間の平均 ( 年間23.9%を上回っています。

収益対業界: VLSの過去 1 年間の収益成長率 ( 26.6% ) Pharmaceuticals業界46.5%を上回りませんでした。

株主資本利益率

高いROE: VLSの自己資本利益率 ( 19.3% ) は低いとみなされます。

Vita Life Sciences 過去の業績

過去 基準チェック /46

主要情報

最近の業績更新

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /46